9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma

Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma

Estimated reading time: < 1 min

Condition: Mesothelioma

Estimated Enrollment: 37

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Completed

Study Results: No Results Available

Outcome Measures: To determine the response to the combination of bevacizumab and erlotinib in previously treated malignant mesothelioma,  To determine the time to tumor progression,  to determine the duration of response, to determine the median and overall survival of patients

Interventions: Erlotinib, Bevacizumab

Phase:

Study Type: Interventional

Study Design: Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: None (Open Label),Primary Purpose: Treatment

Primary Completion Date: March 2007

Completion Date: July 2009

Last  Posted Date: December 26, 2011

Location: The University of Chicago, Chicago, Illinois, United States

Website Link: https://ClinicalTrials.gov/show/NCT00137826

Was this article helpful?
Dislike 0